PYR-41 and Thalidomide Impair Dendritic Cell Cross-Presentation by Inhibiting Myddosome Formation and Attenuating the Endosomal Recruitments of p97 and Sec61 via NF-κB Inactivation

Figure 2

PYR-41 and thalidomide do not increase CD80/CD86 expression in long-term- and short-term-treated conditions. Murine bone marrow-derived DC (cultured for 4 d) conferred PYR-41 (5 μM), thalidomide (30 μM), LPS (10 ng/ml), or DMSO stimulation for 12 (a, b) or 2 (c–f) hrs. The expressions of CD80 and CD86 were determined by flow cytometry. Data were presented as the mean ± SEM, , , and one-way ANOVA with Newman–Keuls post test. One representative from 3 independent experiments was shown.

(a)

(b)

(c)

(d)

(e)

(f)